Bevacizumab treatment of patients with breast cancer results in induction of KLF2, KLF4, KLF6 and KLF9.

The European Union ◽

Primary Tumors ◽

Bevacizumab Treatment ◽

Transcriptional Changes

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We integrated these findings with analysis of a separate microarray dataset studying transcriptional changes globally in the tumors of patients with bladder cancer following treatment with a regimen including bevacizumab (5). We report here the differential and increased expression of the TCDD inducible poly(ADP-ribose) polymerase, TIPARP, in the primary tumors of women treated with bevacizumab for breast cancer.

Bevacizumab treatment of patients with breast cancer is associated with differential expression and up-regulation of hepatic leukemia factor (HLF).

10.31219/osf.io/hwq3p ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

European Union ◽

Clinical Trials ◽

Microarray Data ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the differential and increased expression of the hepatic leukemia factor (5, 6) in the primary tumors of women treated with bevacizumab for breast cancer.

Bevacizumab treatment of patients with breast cancer is associated with induction of AP-1 transcription factor subunits.

10.31219/osf.io/hbn5m ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Transcription Factor ◽

Microarray Data ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Nuclear Factors ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the concomitant induction of AP1 transcription factor subunits JUN, FOS and FOSB in the primary tumors of women with breast cancer treated with bevacizumab, nuclear factors that trigger expression of a host of genes that support the proliferation and growth of cancer (5-13).

Bevacizumab treatment of patients with breast cancer is associated with differential expression and up-regulation of C10orf10.

10.31219/osf.io/w8yc5 ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Microarray Data ◽

Microarray Dataset ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Reading Frame ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel; we integrated these findings with analysis of findings from a separate microarray dataset generated using bevacizumab administration in an experimental model of endometrial cancer (5). We report here the differential and increased expression of open reading frame 10 on chromosome 10, encoded by C10orf10 in the primary tumors of women treated with bevacizumab for breast cancer.

Bevacizumab treatment of patients with breast cancer is associated with induction of MYH11.

10.31219/osf.io/c2qvw ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

European Union ◽

Clinical Trials ◽

Microarray Data ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the induction of the myosin heavy chain MYH11 (5) in the primary tumors of women with breast cancer treated with bevacizumab.

Bevacizumab treatment of patients with breast cancer is associated with induction of SOX17.

10.31219/osf.io/d4u2h ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

European Union ◽

Clinical Trials ◽

Microarray Data ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the striking induction of the SRY-box morphogen transcription factor SOX17 (5-7) in the primary tumors of women with breast cancer treated with bevacizumab.

Bevacizumab treatment of patients with breast cancer is associated with induction of MYLK.

10.31219/osf.io/tcnpf ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Microarray Data ◽

Myosin Light Chain Kinase ◽

Myosin Light Chain ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the induction of the myosin light chain kinase MYLK (5) in the primary tumors of women with breast cancer treated with bevacizumab.

Bevacizumab treatment of patients with breast cancer is associated with differential expression and up-regulation of the thyrotroph embryonic factor, TEF.

10.31219/osf.io/twnau ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

The United States ◽

The European Union ◽

Breast Cancer Patients ◽

Primary Tumors ◽

Bevacizumab Treatment ◽

Embryonic Factor

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the differential and increased expression of the thyrotroph embryonic factor, HLF, in the primary tumors of women treated with bevacizumab for breast cancer. We have recently described the differential expression and up-regulation of TEF in the tumors of breast cancer patients with bevacizumab. Thus, treatment with bevacizumab results in transcriptome-level differential expression and transcriptional induction of two PAR bZIP transcription factors in the tumors of patients with breast cancer.

Bevacizumab treatment of patients with breast cancer is associated with differential expression and up-regulation of the leukemia inhibitory factor receptor (LIFR).

10.31219/osf.io/zb6dm ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Leukemia Inhibitory Factor ◽

Embryonic Stem ◽

The United States ◽

Inhibitory Factor ◽

The European Union ◽

Leukemia Inhibitory Factor Receptor ◽

Primary Tumors ◽

Chemotherapeutic Regimen

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the differential and increased expression of the leukemia inhibitory factor receptor, a gateway to a signaling pathway required for the pluripotency of embryonic stem cells (5, 6), in the primary tumors of women treated with bevacizumab for breast cancer.

DNAJC28 expression associates with survival in triple negative breast cancer.

10.31219/osf.io/v45h2 ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Overall Survival ◽

Cancer Patients ◽

Triple Negative Breast Cancer ◽

Microarray Data ◽

Triple Negative ◽

Breast Cancer Patients ◽

Primary Tumors ◽

Significant Gene

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of DnaJ (Hsp40) homolog, subfamily C, member 28, encoded by DNAJC28 when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, DNAJC28 expression was correlated with overall survival in patients with breast cancer. DNAJC28 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.